CD36 and hepatocellular carcinoma: Mechanistically, CD36 activates the Src pathway and its downstream effectors PI3K/AKT in HCC cells; thus, PI3K or AKT inhibitors or the inhibition of the glycolytic pathway reversed the increased cell proliferation and migration (Luo et al., 2021).